Verification evidence is still being completed.
PDF / print export
Lipigon Pharmaceuticals
Umea, Sweden
- Verified lead
- Johan Liwing
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Lipid Metabolism, Dyslipidemia, RNA Therapeutics, Drug Development, and Clinical Preparation
- Review cycle
- May 2026
- Full address
- Tvistevagen 48 C, SE-907 36 Umea, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Lipigon governance page confirming the Umea address.
- Editorial note
- Lipigon Pharmaceuticals is published because official company materials confirm current leadership, Umea operating address, and a real Swedish lipid-metabolism therapeutics platform.
Lipid Metabolism, Dyslipidemia, RNA Therapeutics, Drug Development, and Clinical Preparation
Official leadership disclosure, Official Umea address disclosure, Therapeutics platform claim
Lipigon Pharmaceuticals is published because official company materials confirm current leadership, Umea operating address, and a real Swedish lipid-metabolism therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Umea, Sweden
Lipigon Pharmaceuticals
Lipid Metabolism, Dyslipidemia, RNA Therapeutics, Drug Development, and Clinical Preparation · Preclinical therapeutics platform
Lipigon Pharmaceuticals runs lipid-metabolism therapeutics, rna drug development, and preclinical program development in Umea, Sweden.
- Lead
- Johan Liwing (verified ↗)
- Address
- Tvistevagen 48 C, SE-907 36 Umea, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Preclinical therapeutics platform
- Capabilities
- Lipid-Metabolism Therapeutics · RNA Drug Development · Preclinical Program Development
- Founded
- 2010
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Johan Liwing
CEO
Full addressTvistevagen 48 C, SE-907 36 Umea, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Preclinical therapeutics platform
Umea, Sweden. Lipid Metabolism, Dyslipidemia, RNA Therapeutics, Drug Development, and Clinical Preparation. Review completed on 21 Mar 2026.
Swedish corporate and therapeutics-development oversight
Official leadership disclosure, Official Umea address disclosure, Therapeutics platform claim
Lipid Metabolism, Dyslipidemia, RNA Therapeutics, Drug Development, and Clinical Preparation
Lipigon Pharmaceuticals is published because official company materials confirm current leadership, Umea operating address, and a real Swedish lipid-metabolism therapeutics platform.
Editorial note
Lipigon Pharmaceuticals is published because official company materials confirm current leadership, Umea operating address, and a real Swedish lipid-metabolism therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Lipid-Metabolism Therapeutics
RNA Drug Development
Preclinical Program Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Therapeutics development workflow
Metabolism-focused R&D systems
Program development infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Lipigon Pharmaceuticals located?
- Lipigon Pharmaceuticals operates from Tvistevagen 48 C, SE-907 36 Umea, Sweden, Umea, Sweden.
- Who runs Lipigon Pharmaceuticals?
- Lipigon Pharmaceuticals is led by Johan Liwing, CEO. Verified 21 Mar 2026.
- What does Lipigon Pharmaceuticals do?
- Lipigon Pharmaceuticals runs lipid-metabolism therapeutics, rna drug development, and preclinical program development in Umea, Sweden. Core capabilities: Lipid-Metabolism Therapeutics, RNA Drug Development, Preclinical Program Development.
Editorial context
Related technical briefs
Briefs that name Umea as a covered market or city.